Abbott, BD and Ascensia Diabetes Care Holdings AG are Dominating in the U.S. At-Home Testing Kits Market in 2020

U.S. At-Home Testing Kits Market is expected to grow with the CAGR of 5.70% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-at-home-testing-kits-market

U.S. at-home testing kits market is a highly consolidated market which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the U.S. at-home testing kits market are introducing strong range of product portfolio. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in August 2019, Drägerwerk AG & Co. KGaA announced that they have launched a new app for their Drager Drug Check 3000 that acts as an advancement of the product and is used for scanning, testing, and recording data of the devices. This has led to an advancement of the product and increased the demand for the products in the forecasted period.

Abbott is the dominating player in the U.S. at-home testing kits market. The other key players existing in the at-home testing kits market include ACON Laboratories, Inc., Rapikit, OraSure Technologies, Inc, BD, Cardinal Health, B. Braun Melsungen AG, Piramal Enterprises Ltd., Siemens Healthcare GmbH, Quidel Corporation, Bionime Corporation, SA Scientific, ARKRAY USA, Inc., Everlywell, Inc., Eurofins Viracor, Inc. (a subsidiary of Eurofins Scientific), Nova Biomedical, AdvaCare Pharma, Atlas Medical UK, LifeScan IP Holdings, LLC, Chembio Diagnostics, Inc., TaiDoc Technology Corporation, Drägerwerk AG & Co. KGaA, AccuBioTech Co., Ltd, F. Hoffmann-La Roche Ltd, Sensing Self, PTE. Ltd, RUNBIO BIOTECH CO.,LTD., Clearblue (a subsidiary of CLEAR BLUE TECHNOLOGIES INC.), PRIMA Lab SA, Mylan N.V. (a subsidiary of Viatris, Inc.), MP BIOMEDICALS, VedaLab and Ascensia Diabetes Care Holdings AG among others.

U.S. At-Home Testing Kits Market

Abbott:

Abbott is headquartered in Illinois, U.S. and was incorporated in 1990. The company is engaged in the manufacturing and providing healthcare products such as medical devices, diagnostic products and nutritional products for consumers. The company has multiple business segments such as established pharmaceutical products, diagnostic products, nutritional products and medical devices among which diagnostic products is the market focused segment. The company provides wide range of products under categories such as consumer and healthcare professional out of which consumer is the market focused category.

For instance,

  • In December 2020, Abbott has introduced new BinaxNOW rapid test for testing COVID-19 virus at home and at very low cost and it provides results in minutes and detects the virus in the early part of the infection and disease. This new launched rapid test kit will help company to acquire more customers and increase their business.

The company has presence across Europe, Asia-Pacific, North America, Latin America and Middle East and Africa. In addition, the company also generates revenue through various subsidiary companies such as Abbott Administration Inc. (U.S.), Abbott Diabetes Care Inc. (U.S.), Abbott Laboratories Argentina S.A. (Argentina), Abbott Australasia Pty Ltd (Australia) among others.

BD:

BD is headquartered in New Jersey, U.S. and was founded in 1906. The company is engaged in providing innovative solutions related to medical research, diagnosis of infectious disease and cancer, infection prevention and surgical equipment. The company has multiple business segments such as medical, life sciences and interventional among which medical is the market focused segment. The company provides wide range of products under categories such as anesthesia delivery, biopsy, bioscience, bio surgery, cervical cancer screening, diabetes, drainage, hazardous drug safety, home care, infection prevention, infusion therapy, interventional specialities, lab automation, medication and supply management, microbiology solutions, molecular diagnostics, patient monitoring and temperature management, prostate health, sharps disposal solutions, software solutions, surgical instruments, syringes and needles, urology and kidney health, vascular access and wound care out of which microbiology solutions is the market focused category.

For instance,

  • In June 2020 BD, the leading U.S. medical technology company has announced that they have completed the acquisition of Straub Medical AG, a privately-held company. With this acquisition, the company has added the valuable expertise and experience of Straub Medical AG and has expanded their product portfolio.

The company has presence across Europe, Asia-Pacific, North America, Latin America and Middle East and Africa. In addition, the company also generates revenue through various subsidiary companies such as Atto BioScience, Inc. (U.S.), BD Holding S. de R.L. de C.V. (Mexico), BD Norge AS (Norway), Becton Dickinson Argentina S.R.L. (Argentina), Becton Dickinson Asia Limited (Hong Kong) among others.

Ascensia Diabetes Care Holdings AG:

Ascensia Diabetes Care Holdings AG is headquartered in Basel, Switzerland and was established in 2006. The company offers wide range of products and solutions related to diabetes and serve the needs of their patients through innovations and expertise. The company provides wide range of products such as contour next blood glucose monitoring systems, contour plus blood glucose monitoring systems and diabetes management solutions out of which contour next blood glucose monitoring systems and contour plus blood glucose monitoring systems are the market focused products.

For instance,

  • In August 2020, Ascensia Diabetes Care Holdings AG and its parent company PHC Holdings Corporation announced that they have entered into a strategic partnership with Senseonics Holdings, Inc. which is a medical technology company who are focused on development and commercialization of continuous glucose monitoring (CGM) systems. PHC Holdings Corporation has made an initial investment of USD 35.00 million. It will help the company to further improve their product offerings as well as leverage the huge customer base of Senseonics Holdings, Inc.

The company has presence across Americas, Europe, Asia-Pacific and Middle East and Africa.